Botulinum toxin as a clinical product: Manufacture and pharmacology

Clinical Applications of Botulinum Neurotoxin

Volumn , Issue , 2014, Pages 7-49

  Pickett, Andy ^a,b  

^a Toxin Science Limited   (United Kingdom)

^b UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

Author keywords

Botulinum neurotoxin; cGMP Drug Substance; Containment; Drug product; Formulation; Pharmacology

Indexed keywords

EID: 85016604523     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-0261-3_2     Document Type: Chapter

References (153)

1. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 70(19):1699-1706
2. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, Simpson LL, So Y (2008) Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 70(19):1691-1698
3. Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, Jabbari B, Kaufmann HC, Schurch B, Silberstein SD, Simpson DM (2008) Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 70(19):1707-1714
4. Scott AB, Rosenbaum A, Collins CC (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12(12):924-927
5. Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB (1985) A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 12(4):314-316
6. Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. N Engl J Med 324(17): 1186-1194
7. Truong DD, Jost WH (2006) Botulinum toxin: clinical use. Parkinsonism Relat Disord 12(6):331-355
8. Bhidayasiri R, Truong DD (2008) Evidence for effectiveness of botulinum toxin for hyperhidrosis. J Neural Transm 115(4):641-645
9. Truong DD, Bhidayasiri R,(2008) Evidence for the effectiveness of botulinum toxin for sialorrhoea. J Neural Transm 115(4):631-635
10. Watts CR, Truong DD, Nye C (2008) Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs. J Neural Transm 115(4):625-630
11. Hexsel C, Hexsel D, Porto MD, Schilling J, Siega C (2011) Botulinum toxin type A for aging face and aesthetic uses. Dermatol Therap 24(1):54-61
12. Jabbari B, Machado D (2011) Treatment of refractory pain with botulinum toxins-an evidence-based review. Pain Med 12(11):1594-1606
13. Linde M, Hagen K, Stovner LJ (2011) Botulinum toxin treatment of secondary headaches and cranial neuralgias: a review of evidence. Acta Neurol Scand Suppl 124(191):50-55
14. Pickett A, Rosales RL (2011) New trends in the science of botulinum toxin-A as applied in dystonia. Int J Neurosci 121(Suppl 1):22-34
15. Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL, Sherris DA (2006) Botulinum toxin to improve facial wound healing: A prospective, blinded, placebocontrolled study. Mayo Clin Proc 81(8):1023-1028
16. Chalhoub M, Harris K, Sasso L, Bourjeily G (2011) The use of botox in the treatment of post cardiac surgery paradoxical vocal cord movement. Heart Lung Circ 20(9):602-604
17. Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 246(4):265-274
18. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C (2008) Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 89(5):799-806
19. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo FS, Albanese A (2009) Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 15(3):224-231
20. Pickett A (2011) Consistent biochemical data are essential for comparability of botulinum toxin type A products. Drugs R D 11(1):97-98, (author reply 98-99)
21. Pickett A (2011) Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data. Clin Ophthalmol 5:1287-1290
22. Bentivoglio AR, Ialongo T, Bove F, De Nigris F, Fasano A (2011) Retrospective evaluation of the dose equivalence of Botox ((R)) and Dysport ((R)) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci:1-7
23. Monheit G, Carruthers A, Brandt F, Rand R (2007) A randomized, double-blind, placebocontrolled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 33(Spec No. 1):51-59
24. Atassi MZ (2004) Basic immunological aspects of botulinum toxin therapy. Mov Disord 19(Suppl 8):68-84
25. Dressler D, Eleopra R (2006) Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res 9(2-3):121-125
26. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53(7):1439
27. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-HulmeA, Koller M (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53(7):1431-1438
28. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Murray JJ, Koller M, Wallace JD (1997) Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49(3):701-707
29. Dressler D, Adib Saberi F, Benecke R (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249(12):1729-1732
30. Flynn TC, Clark RE 2nd (2003) Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg: official publication for American Society for Dermatologic Surgery [et al.] 29(5):519-522
31. Carruthers A, Carruthers J, Flynn TC, Leong MS (2007) Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines. Dermatol Surg: official publication for American Society for Dermatologic Surgery [et al.], 33(1 Spec No.):60-68
32. Oh YJ, Lee NY, Suh DH, Koh JS, Lee SJ, Shin MK (2011) A split-face study using botulinum toxin type B to decrease facial erythema index. J Cosmet Laser Ther 13(5):243-248
33. Strotmeier J, Willjes G, Binz T, Rummel A (2012) Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett 586(4):310-313
34. Panjwani N, O'Keeffe R, Pickett AM (2008) Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J 1(1):153-166
35. http://www.edqm.eu/en-Human-Biologicals-OCABR-611.html. Accessed 24 Jan 2011.
36. http://www.edqm.eu/en/General-European-OMCL-Network-46.html Accessed 24 Jan 2011.
37. Bonventre PF, Kempe LL (1960) Physiology of toxin production by Clostridium botulinum types A and B. I. Growth, autolysis, and toxin production. J Bacteriol 79(1):18-23
38. Rao S, Starr RL, Morris MG, Lin WJ (2007) Variations in expression and release of botulinum neurotoxin in Clostridium botulinum type A strains. Foodborne Pathog Dis 4(2):201-207
39. Day LE, Costilow RN (1964) Physiology of the sporulation process in Clostridium botulinum I. Correlation of morphological changes with catabolic activities, synthesis of dipicolinic acid, and development of heat resistance. J Bacteriol 88:690-694
40. Day LE, Costilow RN (1964) Physiology of the sporulation process in Clostridium botulinum II. Maturation of forespores. J Bacteriol 88:695-701
41. Bradshaw M, Marshall KM, Heap JT, Tepp WH, Minton NP, Johnson EA (2010) Construction of a nontoxigenic Clostridium botulinum strain for food challenge studies. Appl Environ Microbiol 76(2):387-393
42. Cooksley CM, Davis IJ, Winzer K, Chan WC, Peck MW, Minton NP (2010) Regulation of neurotoxin production and sporulation by a putative agrBD signaling system in proteolytic Clostridium botulinum. Appl Environ Microbiol 76(13):4448-4460
43. Bradshaw M, Dineen SS, Maks ND, Johnson EA (2004) Regulation of neurotoxin complex expression in Clostridium botulinum strains 62A, Hall A-hyper, and NCTC 2916. Anaerobe 10(6):321-333
44. Bonventre PF, Kempe LL (1959) Physiology of toxin production by Clostridium botulinum types A and B. II. Effect of carbohydrate source on growth, autolysis, and toxin production. Appl Microbiol 7(6):372-374
45. Bonventre PF, Kempe LL (1959) Physiology of toxin production by Clostridium botulinum types A and B. III. Effect of pH and temperature during incubation on growth, autolysis. and toxin production. Appl Microbiol 7(6):374-377
46. Bonventre PF, Kempe LL (1960) Physiology of toxin production by Clostridium botulinum types A and B. IV. Activation of the toxin. J Bacteriol 79(1):24-32
47. Schantz EJ, Johnson EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56(1):80-99
48. Pickett A, Perrow K (2009) Composition and molecular size of Clostridium botulinum type A toxin-hemagglutinin complex. Protein J 28(5):248-249, (discussion 250-251)
49. Pickett A (2007) Tribute to an enigma: the life and times of Ivan Clifford Hall, 1885-1975, in 44th annual meeting of the Interagency Botulism Research Coordinating Committee. Asilomar, CA
50. Hall IC (1928) A collection of anaerobic bacteria. Science 68(1754):141-142
51. Frevert J (2010) Content of botulinum neurotoxin in botox(r)/vistabel(r), dysport(r)/azzal-ure(r), and xeomin(r)/bocouture(r). Drugs R D 10(2):67-73
52. Fang PK, Raphael BH, Maslanka SE, Cai S, Singh BR (2010) Analysis of genomic differences among Clostridium botulinum type A1 strains. BMC Genomics 11(1):725
53. Zhang L, Lin WJ, Li S, Aoki KR (2003) Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum typeA-Hall (Allergan) strain. Gene315:21-32
54. Zhang L, Lin W-J, Li S, Aoki KR (2003) Corrigendum to "complete DNA sequences of the botulinum neurotoxin complex of Clostridium botolinum type A-Hall (Allergan) strain" [Gene 315 (2002) 21-32]. Gene 322(0):187
55. Sebaihia M, Peck MW, Minton NP, Thomson NR, Holden MT, Mitchell WJ, Carter AT, Bentley SD, Mason DR, Crossman L, Paul CJ, Ivens A, Wells-Bennik MH, Davis IJ, Cerdeno- TarragaAM, Churcher C, Quail MA, Chillingworth T, Feltwell T, FraserA, Goodhead I, Hance Z, Jagels K, Larke N, Maddison M, Moule S, Mungall K, Norbertczak H, Rabbinowitsch E, Sanders M, Simmonds M, White B, Whithead S, Parkhill J (2007) Genome sequence of a proteolytic (group I) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes. Genome Res 17(7):1082-1092
56. http://www.kobio.org/kobio/fileupload/downloadFile.bio?fnum=3&seq=1 meditoxin. Accessed 23 Jan 2012
57. Zhao YJ, Wei R, Liu C (2010) Cloning and sequencing of complete BoNT gene of Clostridium botulinum type A for therapy. Chin J Biol 23(6):598-601
58. Siegel LS, Metzger JF (1980) Effect of fermentation conditions on toxin production by Clostridium botulinum type B. Appl Environ Microbiol 40(6):1023-1026
59. Setler P (2000) The biochemistry of botulinum toxin type B. Neurology 55(12 Suppl 5):22-28
60. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D (1997) Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 224(2):91-94
61. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256(3):135-138
62. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C (2002) Different types of botulinum toxin in humans. Naunyn Schmiedebergs Arch Pharmacol 365(Suppl 2):R18
63. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C (2004) Different types of botulinum toxin in humans. Mov Disord 19(Suppl 8):S53-S59
64. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C, Dressler D (2006) Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F. Neurotox Res 9(2-3):127-131
65. Lautenschlager M, Maslanka SE, Paul PA, Kalb SR, Barr JR, Raphael BH (2012) Recovery and detection of botulinum neurotoxins from a nonporous surface. J Microbiol Methods 92(3):278-280
66. Munro K, Lanser J, Flower R (1999) A comparative study of methods to validate formaldehyde decontamination of biological safety cabinets. Appl Environ Microbiol 65(2):873-876
67. Johnston MD, Lawson S, Otter JA (2005) Evaluation of hydrogen peroxide vapour as a method for the decontamination of surfaces contaminated with Clostridium botulinum spores. J Microbiol Methods 60(3):403-411
68. World Health Organisation (2003) Laboratory biosafety manual. Geneva, Switzerland. 99
69. Centers for Disease Control and Prevention, National Institutes of Health (2009) Biosafety in microbiological and biomedical laboratories. US Department of Health and Human Services, Public Health Service, p. 415
70. Advisory Committee on Dangerous Pathogens (2001) The management, design and operation of microbiological containment laboratories. HSE Books, Suffolk, p. 67
71. http://www.bt.cdc.gov/agent/agentlist-category.asp. Accessed 17 March 2011
72. http://www.selectagents.gov. Accessed 17 March 2011
73. Select Agents and Toxins Security Information Document. Prepared by US Department of Health and Human Services (HHS) Center for Disease Control and Prevention (CDC) and US Department of Agriculture Animal and Plant Health Inspection Service (APHIS), March 8 2007
74. Health and Safety Executive (HSE), Advisory Committee on Dangerous Pathogens (ACDP), (2004) The approved list of biological agents, HMSO. United Kingdom
75. Centers for Disease Control and Prevention (2011) Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR 60(42):1454-1455
76. Henkel JS, Tepp WH, Przedpelski A, Fritz RB, Johnson EA, Barbieri JT (2011) Subunit vaccine efficacy against botulinum neurotoxin subtypes. Vaccine 29(44):7688-7695
77. White DM, Pellett S, Jensen MA, Tepp WH, Johnson EA, Arnason BG (2011) Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells. Infect Immun 79(8):3388-3396
78. Abrams A, Kegeles G, Hottle GA (1946) The purification of toxin from Clostridium botulinum type A. J Biol Chem 164:63-79
79. Lamanna C, McElroy OE, Eklund HW (1946) The purification and crystallization of Clostridium botulinum type A toxin. Science 103(2681):613-614
80. Hambleton P, Capel B, Bailey N et al (1981) Production, purification and toxoiding of Clostridium botulinum type A toxin. In: Lewis Jr GE, Angel PS (ed) Biomedical aspects of botulism, Academic Press Inc, New York
81. Hambleton P (1992) Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol 239(1):16-20
82. Duff JT, Wright GG, Klerer J, Moore DE, Bibler RH (1957) Studies on immunity to toxins of Clostridium botulinum. I. A simplified procedure for isolation of type A toxin. J Bacteriol 73(1):42-47
83. Schantz EJ, Johnson EA (1997) Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 40(3):317-327
84. Aoki KR (1999) Preclinical update on BOTOX(r) (botulinum toxin type A)-purified neurotoxin complex relative to other botulinurn neurotoxin preparations. Eur J Neurol 6:s3-s10
85. Lietzow MA, Gielow ET, Le D, Zhang J, Verhagen MF (2008) Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis. Protein J 27(7-8):420-425
86. Lietzow MA, Gielow ET, Le D, Zhang J, Verhagen MF (2008) Composition and molecular size of Clostridium botulinum type A toxin-hemagglutinin complex. Protein J 28(5):250-251
87. FDA CBER Establishment Inspetion Report, Allergan, Inc, October 13-20 1997: redacted
88. Wortzman MS, Pickett A (2009) The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use. Aesthet Surg J 29(6):S34-S42
89. Pickett A, Caird D (2008) Comparison of type a botulinum toxin products in clinical use. J Clin Pharm Ther 33(3):327-328
90. Pickett A, Perrow K (2010) Formulation composition of botulinum toxins in clinical use. J Drugs Dermatol 9(9):1085-1091
91. Pickett A (2013) Reviews of botulinum toxin products in aesthetic use must be accurate, clear and avoid speculation. Clin Pharmacol: Advances and Applications 5:149-152
92. Lorenc ZP, Kenkel JM, Fagien S, Hirmand H, Nestor MS, Sclafani AP, Sykes JM, Waldorf HA (2013) IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing. Aesthet Surg J 33(Suppl 1):18S-22S
93. Bigalke H, Frevert J (2011). Therapeutic composition comprising a botulinum neurotoxin. US patent 7,964,199 B1 June 21 2011
94. Callaway JE, Arezzo JC, Grethlein AJ (2001) Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg 20(2):127-136
95. Callaway JE (2004) Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Clin Dermatol 22(1):23-28
96. Ohishi I, Sakaguchi G (1977) Activation of botulinum toxins in the absence of nicking. Infect Immun 17(2):402-407
97. Evans DM, Williams RS, Shone CC, Hambleton P, Melling J, Dolly JO (1986) Botulinum neurotoxin type B. Its purification, radioiodination and interaction with rat-brain synaptosomal membranes. Eur J biochem/FEBS 154(2):409-416
98. Goodnough MC, Johnson EA (1992) Stabilization of botulinum toxin type A during lyophilization. Appl Environ Microbiol 58(10):3426-3428
99. Elston JS (1990) Botulinum toxin A in clinical medicine. J Physiol (Paris) 84(4):285-289
100. Hambleton P, Cohen HE, Palmer BJ, Melling J (1992) Antitoxins and botulinum toxin treatment. BMJ 304(6832):959-960
101. Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P (1993) Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43(9):1715-1718
102. Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9(2):213-217
103. Botox prescribing information, revised October 2006, Allergan Inc, CA
104. Botox prescribing information, October 2010, Allergan Inc, CA reference numbers 71580US11B & 72284US12B
105. Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, Boodhoo T, Miller-Messana MA, Demos G, James L, Beddingfield F, VanDenburgh A, Chapman MA, Brin MF (2010) Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX(R)) across multiple indications. Mov Disord 25(13):2211-2218
106. Racette BA, McGee-Minnich L, Perlmutter JS (1999) Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation. Clin Neuropharmacol 22(6):337-339
107. Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60(7):1186-1188
108. Naumann M, Yakovleff A, Durif F, B C D P S Group (2002) A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 249(1):57-63
109. Aoki KR (2005) Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin 45(3):25-37
110. Atassi MZ, Dolimbek BZ, Steward LE, Aoki KR (2007) Molecular bases of protective immune responses against botulinum neurotoxin A-how antitoxin antibodies block its action. Crit Rev Immunol 27(4):319-341
111. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ (2007) Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 44(5):1029-1041
112. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32(4):213-218
113. Pickett A, Panjwani N, O'Keeffe RS (2003) Potency of type A botulinum toxin preparations in clinical use, in 40th annual meeting of the Interagency Botulinum Research Coordinating Committee. Atlanta, USA
114. Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19(Suppl 8):S92-S100
115. Stell R, Coleman R, Thompson P, Marsden CD (1988) Botulinum toxin treatment of spasmodic torticollis. BMJ 297(6648):616
116. Racette BA, Stambuk M, Perlmutter JS (2002) Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024). Mov Disord 17(5):1098-1100
117. Panjwani N, Pickett A, O'Keeffe R (2005) Botulinum type A toxins in clinical use: a comparison of specific potency and protein content. Neurotox Res 9(2-3):225-254
118. Pickett A, O'Keeffe R, Panjwani N (2007) The protein load of therapeutic botulinum toxins. Eur J Neurol 14(4):e11
119. Dodd SL, Rowell BA, Vrabas IS, Arrowsmith RJ, Weatherill PJ (1998) A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function. Eur J Neurol 5(2):181-186
120. Dodd SL, Selsby J, Payne A, Judge A, Dott C (2005) Botulinum neurotoxin type A causes shifts in myosin heavy chain composition in muscle. Toxicon 46(2):196-203
121. Pickett A, O'Keeffe R, Judge A, Dodd S (2008) The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations. Toxicon 52(3):455-464
122. Cichon JV Jr, McCaffrey TV, Litchy WJ, Knops JL (1995) The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Laryngoscope 105(2):144-148
123. Aoki KR, Peng K, Siddiqui T, Spanoyannis A (1995) Pharmacology of BOTOX (botulinum toxin type A) purified neurotoxin complex: local versus systemic muscle activity measurements in mice. Eur J Neurol 2(Suppl 3):3-9
124. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125724Orig1s001MedR.pdf. Accessed 22 Jan 2012
125. Karst KR (2004) Presages to the coming war over generic biologics. J Generic Med 1(2): 155-163
126. Jost WH, Blumel J, Grafe S (2007) Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 67(5):669-683
127. Quarta M (2009) Bilateral comparison of two botulinum toxin type A solutions for latero-orbital facial lines. Double blind study of Botox(c)versus Xeomin(c). Journal für Ästhetische Chirurgie 2(4):199-202
128. Bowe C (2011) Biologic drugs shelf life dating periods: how long can you go? Scrip Intelligence
129. Grein S, Fink K (2009) Complexing proteins are not required for stability of botulinum neurotoxin type A preparations. J Neurol Sci 285(S1):S299
130. Grein S, Mander G, Fink K (2011) Stability of botulinum neurotoxin type A, devoid of complexing proteins. Botulinum J 2(1):49-57
131. Matejtschuk P, Dash CH, Gascoigne EW (2000) Production of human albumin solution: a continually developing colloid. Br J Anaesth 85(6):887-895
132. Hexsel D, Rutowitsch MS, De Castro LC, Do Prado DZ, Lima MM (2009) Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection. Dermatol Surg 35:933-940
133. Yang GC, Chiu RJ, Gillman GS (2008) Questioning the need to use botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox. Arch Facial Plast Surg 10(4):273-279
134. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM (2005) Botulinum toxin type A injections: adverse events reported to the US food and drug administration in therapeutic and cosmetic cases. J Am Acad Dermatol 53(3):407-415
135. Pickett A (2011) Researcher predicts future generations of neurotoxins. Aesth Guide July/August:36-44
136. Myobloc prescribing information at http://www.myobloc.com/hp_about/PI_5-19-10.pdf. Accessed 22 Jan 2012
137. http://www.primequal.com/home.php. Accessed 22 Jan 2012
138. http://medical-dictionary.thefreedictionary.com/pharmacology. Accessed 22 January 2012
139. Simpson L (2013) The life history of a botulinum toxin molecule. Toxicon 68:40-59
140. Aoki KR (2003) Pharmacology and immunology of botulinum toxin type A. Clin Dermatol 21(6):476-480
141. Aoki KR (2004) Pharmacology of botulinum neurotoxins. Operative techniques in otolaryngology-head and neck surgery 15(2):81-85
142. Rosales RL, Bigalke H, Dressler D (2006) Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 13(Suppl 1):2-10
143. Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 29(23):1761-1768
144. Poulain B, Popoff MR, Molgo J (2008) How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J 1(1):14-87
145. Pickett A (2012) Animal studies with botulinum toxins may produce misleading results. Anesth Analg 115(3):736, author reply 736-7
146. Clowry GJ, Walker L, Davies P (2006) The effects of botulinum neurotoxinA induced muscle paresis during a critical period upon muscle and spinal cord development in the rat. Exp Neurol 202(2):456-469
147. Choi WH, Song CW, Kim YB, Ha CS, Yang GH, Woo HD, Jung HH, Koh WS (2007) Skeletal muscle atrophy induced by intramuscular repeated dose of botulinum toxin type A in rats. Drug Chem Toxicol 30(3):217-227
148. Favre-Guilmard C, Auguet M, Chabiier PE (2009) Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol 617(1-3):48-53
149. Aoki KR, Ranoux D, Wissel J (2006) Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol: the official journal of the European Federation of Neurological Societies 13(Suppl 4):10-19
150. Pickett A (2009) Dysport: pharmacological properties and factors that influence toxin action. Toxicon 54(5):683-689
151. Hale M, Riding S, Singh BR (2010) Near-infrared imaging of balb/c mice injected with a detoxified botulinum neurotoxin A. Botulinum J 1(4):431-441
152. Yang W, Lindo P, Riding S, Chang T-W, Cai S, Van T, Kukreja R, Zhou Y, Vasa K, Singh BR (2008) Expression, purification and comparative characterisation of enzymatically deactivated recombinant botulinum neurotoxin type A. Botulinum J 1(2):219-241
153. Baskaran P, Lehmann TE, Topchiy E, Thirunavukkarasu N, Cai S, Singh BR, Deshpande S, Thyagarajan B (2013) Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions. Toxicon 72:71-80